| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
Eburicoic acid targets multiple pathways involved in inflammation, oxidative stress, and cell proliferation. It has been shown to modulate the activity of several enzymes and signaling molecules, including superoxide dismutase (SOD), nitric oxide (NO), tumor necrosis factor-alpha (TNF-α), nitric oxide synthase (NOS), cyclooxygenase (COX), and cytochrome P450 enzymes (e.g., CYP17). Its anti-inflammatory effects are mediated through the decrease of inflammatory cytokines, such as TNF-α and interleukin-1β (IL-1β), and an increase in antioxidant enzyme activity, such as catalase (CAT), SOD, and glutathione peroxidase (GPx). By reducing oxidative stress and inflammation, eburicoic acid protects the liver from CCl4-induced hepatic damage. In cancer cells, it has been shown to promote reactive oxygen species (ROS) generation and ATP depletion, leading to endoplasmic reticulum stress, elevated cytosolic calcium, and induction of autophagy. This multi-targeted mechanism of action underlies its diverse pharmacological activities.
|
|---|---|
| ln Vitro |
In vitro, eburicoic acid effectively reduces the viability of human hepatoma Hep 3B cells. It promotes reactive oxygen species generation and ATP depletion, leading to endoplasmic reticulum stress, elevated cytosolic calcium, and induction of autophagy. It also shows a moderate vasorelaxant effect on rat aorta. The compound exhibits growth inhibitory activity against a human cancer cell line, with a GI50 of 10000.0 nM. These in vitro studies are crucial for understanding its anticancer mechanisms and for evaluating its potential as a therapeutic agent.
|
| ln Vivo |
In vivo, eburicoic acid and its related compound dehydroeburicoic acid have been shown to protect the liver from CCl4-induced liver damage in mice. They have analgesic and anti-inflammatory effects, as demonstrated in various animal models. For instance, treatment with eburicoic acid significantly inhibited acetic acid-induced writhing responses and formalin-induced pain in the late phase. In an anti-inflammatory test, eburicoic acid decreased paw edema at the fourth and fifth hour after λ-carrageenan administration and increased the activities of CAT, SOD, and GPx in the paw edema tissue. It also significantly attenuated the malondialdehyde (MDA), NO, TNF-α, and IL-1β levels in either edema paw or serum. These findings confirm its potent anti-inflammatory and hepatoprotective activities in living organisms.
|
| Enzyme Assay |
Non-cell-based assays for eburicoic acid involve measuring its effects on enzyme activities and biochemical parameters. For example, antioxidant enzyme activities (e.g., SOD, CAT, GPx) and inflammatory cytokine levels (e.g., TNF-α, IL-6) can be measured in liver homogenates or serum using colorimetric or ELISA-based methods. The compound's ability to scavenge free radicals or inhibit lipid peroxidation can also be assessed in cell-free systems. These assays are fundamental for characterizing its biochemical properties and mechanism of action.
|
| Cell Assay |
For in vitro cellular experiments, human hepatoma Hep 3B cells are treated with eburicoic acid at various concentrations (e.g., 0-100 µM) for 24 hours. Cell viability is measured using MTT or CCK-8 assays. ROS generation is measured using fluorescent probes such as DCFH-DA. ATP levels are measured using luciferase-based assays. Autophagy markers (e.g., LC3-II, Beclin-1) are assessed by Western blot. These experiments are essential for studying its cellular effects and mechanisms.
|
| Animal Protocol |
In vivo animal studies typically involve mice. To induce liver damage, CCl4 is administered. Eburicoic acid is administered orally or intraperitoneally before or after CCl4 treatment. Liver function markers (ALT, AST) and histopathology are assessed. Inflammatory cytokines and antioxidant enzyme activities are measured in liver tissue. These studies are crucial for evaluating its efficacy and safety in a living organism.
|
| ADME/Pharmacokinetics |
No detailed pharmacokinetic data for eburicoic acid are available in the public literature. The compound is soluble in chloroform, dichloromethane, ethyl acetate, DMSO, and acetone.
|
| Toxicity/Toxicokinetics |
Toxicological data for eburicoic acid are not available in the public literature.
|
| References |
|
| Additional Infomation |
Eburicoic acid has reportedly been found in Laetiporus versisporus, Porotheleum, and other organisms with available data.
Eburicoic acid is a triterpenoid with significant anti-liver cancer effects and distinctive mechanisms. It has been isolated from the root of Wolfiporia cocos (Schw.) Ryv. and Antrodia camphorata. It exhibits anti-inflammatory and antioxidant activity, thereby protecting the liver from CCl4-induced hepatic damage. It is used in pharmacological research for its potential in treating cancer, inflammatory, and metabolic diseases. |
| Molecular Formula |
C31H50O3
|
|---|---|
| Molecular Weight |
470.73
|
| Exact Mass |
470.376
|
| CAS # |
560-66-7
|
| PubChem CID |
73402
|
| Appearance |
White to off-white solid
|
| Density |
1.05g/cm3
|
| Boiling Point |
572.6ºC at 760mmHg
|
| Flash Point |
314.1ºC
|
| Index of Refraction |
1.54
|
| LogP |
7.789
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
34
|
| Complexity |
881
|
| Defined Atom Stereocenter Count |
7
|
| SMILES |
CC(C)C(=C)CCC(C1CCC2(C1(CCC3=C2CCC4C3(CCC(C4(C)C)O)C)C)C)C(=O)O
|
| InChi Key |
UGMQOYZVOPASJF-OXUZYLMNSA-N
|
| InChi Code |
InChI=1S/C31H50O3/c1-19(2)20(3)9-10-21(27(33)34)22-13-17-31(8)24-11-12-25-28(4,5)26(32)15-16-29(25,6)23(24)14-18-30(22,31)7/h19,21-22,25-26,32H,3,9-18H2,1-2,4-8H3,(H,33,34)/t21-,22-,25+,26+,29-,30-,31+/m1/s1
|
| Chemical Name |
(2R)-2-[(3S,5R,10S,13R,14R,17R)-3-hydroxy-4,4,10,13,14-pentamethyl-2,3,5,6,7,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-17-yl]-6-methyl-5-methylideneheptanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1244 mL | 10.6218 mL | 21.2436 mL | |
| 5 mM | 0.4249 mL | 2.1244 mL | 4.2487 mL | |
| 10 mM | 0.2124 mL | 1.0622 mL | 2.1244 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
